These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care. Altman DJ Dermatol Clin; 2000 Apr; 18(2):287-96. PubMed ID: 10791155 [TBL] [Abstract][Full Text] [Related]
15. How Genentech Novartis stifled a promising drug: biotech firm tried to pursue a peanut allergy inject, but contract got in way; Zach avoids a "kiss of death". Hamilton DP Wall St J (East Ed); 2005 Apr; ():A1, A10. PubMed ID: 15926244 [No Abstract] [Full Text] [Related]
16. Discontinued drugs in 2008: oncology drugs. Williams R Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760 [TBL] [Abstract][Full Text] [Related]
17. Drugs with breakthrough status charm investors. Senior M Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748 [No Abstract] [Full Text] [Related]
18. Drug pipeline: 3Q15. DeFrancesco L Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135 [No Abstract] [Full Text] [Related]
19. Off-label uses and side effects of infliximab. Scheinfeld N J Drugs Dermatol; 2004; 3(3):273-84. PubMed ID: 15176162 [TBL] [Abstract][Full Text] [Related]
20. The role of the pharmaceutical industry in drug development in dermatology. Cauwenbergh G Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516 [No Abstract] [Full Text] [Related] [Next] [New Search]